Mandate

Vinge has advised SEB in connection with the issuance of Additional Tier 1 Capital of USD 900 million

Vinge has advised Skandinaviska Enskilda Banken AB (publ) as to Swedish law in connection with the issuance of Additional Tier 1 Capital (AT1) of USD 900 million to optimise its capital structure.

The issuance is in the form of a debt instrument with automatic conversion into Class A shares if the Common Equity Tier 1 capital ratio of the bank falls below a certain level. The instruments will be listed on Euronext Dublin.

Vinge’s team consisted mainly of Charlotte Levin, Albert Wållgren, Malte Hedlund and Boris Kotur.

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026